TMC8

Across TCGA pan-cancer cohorts, TMC8 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMC8 data layer compared with 26 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher TMC8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMC8 expression acts as an unfavorable survival marker.

SCLC, STAD, and ESCA are the cancer types where TMC8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	OS	Median	II,III,IV	0.137	0.700	<.001	42	view →
STAD	DFS	Median	All	0.210	0.709	.014	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
COAD	DFS	Median	All	0.176	0.697	.001	6	view →
SKCM	OS	Median	IV	0.415	0.861	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMC8–SCLC (OS)

Open the SCLC breakdown →